A ready-to-use, thermoresponsive, and extended-release delivery system for the paranasal sinuses.

Published on Sep 23, 2021in Drug Delivery and Translational Research4.617
· DOI :10.1007/S13346-021-01069-3
Andrea L. Schilling3
Estimated H-index: 3
(University of Pittsburgh),
Erin Cannon (University of Pittsburgh)+ 3 AuthorsSteven R. Little33
Estimated H-index: 33
Sources
Abstract
A drug delivery system for the paranasal sinuses consisting of a freeze-dried thermoresponsive hydrogel with degradable microspheres, called FD-TEMPS (Freeze Dried—Thermogel, Extended-release Microsphere-based delivery to the Paranasal Sinuses), was developed. Glass transition temperatures (Tg′) of the maximally freeze concentrated solutions consisting of poly(N-isopropylacrylamide) (pNIPAAm) and polyethylene glycol (PEG) were determined by differential scanning calorimetry, which informed optimization of the thermogel formulation. By replacing low molecular weight (MW) PEG (200 Da) with a higher MW PEG (2000 Da), the resulting freeze-dried gel exhibited a brittle texture, porous structure, and low residual moisture (< 3% measured by thermal gravimetric analysis). When combined with poly(lactic-co-glycolic acid) microspheres (PLGA MSs) and freeze dried, the complete system (FD-TEMPS) exhibited enhanced shelf-stability. Specifically, the smooth, spherical morphology of the MSs and initial release kinetics were maintained following 6 weeks of storage under ambient conditions. Furthermore, FD-TEMPS remained in place after application to a simulated mucosal surface, suggesting that it could be more uniformly distributed along the sinonasal mucosa in vivo. Freeze drying enables this delivery system to be stored as a ready-to-use product for better ease of clinical translation without compromising the thermoresponsive or sustained release characteristics that would enable local delivery of therapeutics to the sinonasal mucosa.
📖 Papers frequently viewed together
1995
2018
4 Authors (Odonchimeg M, ..., W K Lee)
References35
Newest
#1Andrea L. Schilling (University of Pittsburgh)H-Index: 3
#2Adam R Carcella (University of Pittsburgh)H-Index: 1
Last. Steven R. LittleH-Index: 33
view all 8 authors...
The current clinical goal for managing chronic rhinosinusitis (CRS), a heterogenous disease of the paranasal sinuses, is to control inflammation, yet adjunct therapies that promote mucosal regeneration can improve the long-term health of the upper airways. The small natural openings to the sinuses, however, limit the efficacy of traditional drug delivery methods (i.e., nasal sprays and irrigation). Accordingly, a conformable thermoresponsive and controlled release system ("TEMPS", Thermogel, Ext...
Source
#1Andrea L. Schilling (University of Pittsburgh)H-Index: 3
#2Yalcin Kulahci (University of Pittsburgh)H-Index: 15
Last. Steven R. LittleH-Index: 33
view all 6 authors...
Abstract Delivering localized treatment to the paranasal sinuses for diseases such as chronic rhinosinusitis (CRS) is particularly challenging because of the small natural openings leading from the sinuses that can be further obstructed by presence of inflammation. As such, oral steroids, topical nasal sprays or irrigation, and surgery can be utilized to treat persistent sinonasal inflammation, but there exists a need for post-operative options for long-term steroid delivery to prevent disease r...
Source
#1Joseph K. Han (EVMS: Eastern Virginia Medical School)H-Index: 30
#2Robert C. Kern (NU: Northwestern University)H-Index: 67
BACKGROUND: Chronic rhinosinusitis (CRS) causes severe symptoms that lead to poor quality of life. When optimal medical therapy does not improve CRS symptoms, then endoscopic sinus surgery (ESS) can be used in patients with persistent symptoms and radiographic evidence of CRS to improve patients' symptoms and quality of life. Despite appropriate and complete sinus surgery, there can be issues after sinus surgery such as synechiae formation and recurrence of polyps in certain CRS patients that ca...
Source
#1Richard G. Douglas (University of Auckland)H-Index: 27
#2Alkis J. PsaltisH-Index: 33
Last. Yina KuangH-Index: 1
view all 6 authors...
Background: Chronic rhinosinusitis (CRS) patients who fail medical management have few treatment options other than endoscopic sinus surgery (ESS). A novel biodegradable mometasone furoate drug delivery system (LYR-210) providing continuous topical steroid therapy to sinonasal mucosa over 24 weeks was developed to treat unoperated CRS patients who have failed medical management prior to ESS. LYR-210 was designed to slowly expand in the middle meatus, ensuring efficient drug delivery as mucosal s...
Source
#1Elena Bellotti (University of Pittsburgh)H-Index: 4
#2Morgan V. FedorchakH-Index: 14
Last. Steven R. LittleH-Index: 33
view all 4 authors...
Low patient compliance and poor bioavailability of ophthalmic medications are the main limitations of topical eye drops. A potential solution to these disadvantages could be provided by thermoresponsive hydrogels, which could be used as the basis for a gelling eye drop for long-term release of therapeutics. We previously reported such a system capable of being retained in the lower fornix of rabbits, continuously releasing an anti-glaucoma drug for one month. Here, we sought to improve the prope...
Source
BACKGROUND: Topical intranasal corticosteroid sprays (INCSs) are standard treatment for nasal polyps (NPs), but their efficacy is reduced by poor patient compliance and impaired access of drug to the sinus mucosa. A corticosteroid-eluting sinus implant was designed to address these limitations in patients with recurrent polyposis after sinus surgery by delivering 1350 μg of mometasone furoate (MF) directly to the ethmoid sinus mucosa over approximately 90 days. METHODS: A randomized, sham-contro...
Source
#1Upma SharmaH-Index: 13
#2Danny ConcaghH-Index: 1
Last. Maria PalasisH-Index: 1
view all 13 authors...
Metallic stents have been widely used in coronary angioplasty. Here, the authors develop a resorbable self-expanding stent from polymeric elastomers with high mechanical strength for coronary applications.
Source
#1Jasmim Leal (University of Texas at Austin)H-Index: 7
#2Hugh D. C. Smyth (University of Texas at Austin)H-Index: 34
Last. Debadyuti Ghosh (University of Texas at Austin)H-Index: 13
view all 3 authors...
Abstract Mucus is a selective barrier to particles and molecules, preventing penetration to the epithelial surface of mucosal tissues. Significant advances in transmucosal drug delivery have recently been made and have emphasized that an understanding of the basic structure, viscoelastic properties, and interactions of mucus is of great value in the design of efficient drug delivery systems. Mucins, the primary non-aqueous component of mucus, are polymers carrying a complex and heterogeneous str...
Source
Abstract The aim of this study was the production of ondansetron hydrochloride loaded lyophilized insert for nasal delivery. The nasal insert was prepared by the lyophilisation technique using Chitosan–gellan gum polyelectrolyte complex as the polymer matrix. The ondansetron loaded inserts were evaluated with respect to water uptake, bioadhesion, drug release kinetic study, ex vivo permeation study, and in vivo study. Lyophilised nasal inserts were characterized by differential scanning calorime...
Source
#1Swapnil K. Pansare (MedImmune)H-Index: 3
#2Sajal M. Patel (MedImmune)H-Index: 13
Glass transition temperature is a unique thermal characteristic of amorphous systems and is associated with changes in physical properties such as heat capacity, viscosity, electrical resistance, and molecular mobility. Glass transition temperature for amorphous solids is referred as (T g), whereas for maximally freeze concentrated solution, the notation is (T g′). This article is focused on the factors affecting determination of T g′ for application to lyophilization process design and frozen s...
Source
Cited By0
Newest
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.